• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
188198 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  & I! S* _/ |1 m& {

; ]5 T  a% G6 q: @8 A0 c; m5 ?. w: H1 b8 N" s! f: t0 i/ x
Sub-category:
3 k; k8 ~0 T- q; v/ G4 J  x+ V- HMolecular Targets + |9 @( {- ^( t/ G0 u1 O7 k0 x/ ]  H

* z: y# i& h: E7 U7 F. D  Q! h* \4 y4 \
Category:, }3 j( [. L5 D% {6 O
Tumor Biology ; D( Z3 W- r# j9 z8 i
8 Q! `4 l' M7 B1 g7 T" ]% l

7 t7 x7 {) h5 q6 z$ Q* C* IMeeting:! V/ w& I) w/ }0 P  U
2011 ASCO Annual Meeting . W5 c( c- r- W  d4 \0 d+ j" |) s! |

( x  b1 O. O) U; Q7 Z9 x! d- M4 r4 w
Session Type and Session Title:
3 |: ]( v0 y+ l+ l* v( K3 LPoster Discussion Session, Tumor Biology ' e! i# S/ P& h) D- b
+ Z% f! X+ |5 M3 s3 K

, {1 c3 X; F+ W/ H$ v( KAbstract No:
$ H3 X- n$ _) v* e: E0 t2 U- k$ Z& ]10517 / [: t+ m" Y  }" _" e7 g7 A1 D# u, t5 y) b

" N$ ^: q- A- W' k+ ~) D1 u8 i" v$ K/ X& i/ `0 Z
Citation:
* m; J* G0 G2 L0 lJ Clin Oncol 29: 2011 (suppl; abstr 10517) " w/ b1 b! f0 X4 f% p! j

" G# U6 K8 s) @) E4 Y
4 q& A, ?6 J! aAuthor(s):
) ]# o# E, }* G( {J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ) j6 w' A3 g$ ^8 B& D1 j& B
1 ]) i2 W+ {- W, q# N; o; H

$ Q* k% i  \9 R( R, \: _  Q8 y6 c, u
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
5 `$ c. i3 y' {
' g& ~  _4 _* O# k+ j1 AAbstract Disclosures' s: h; |; [% K6 v
+ C: E, z; ]9 m: v7 A  x& @
Abstract:0 F  v7 G* @+ \

; Y+ f, f6 J) u( E3 f8 @) k" A! K+ ~- C
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
# R3 G6 U9 a! L/ q
/ S8 J. Z2 f$ x9 z" H/ D
' E: v) w& h" c
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 6 F  t' f5 x* M) r
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

& {# @5 H" V" E) V4 I化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
! y& c5 u0 t, i, \1 R4 n+ p易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。3 \( k% j5 X$ h" ^& ^& Z3 X2 f
ALK一个指标医院要900多 ...

& r8 t; J4 ?' N6 q5 s平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
/ h; D+ _' b4 E4 T3 D( A. k
' a  A* z& b7 V' @现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表